1 LATANOPROST | 370 of 2660 | 7950 prescriptions Less than 1% of all prescriptions | | 1690 patients 26% of all patients | < 11 | |
2 TIMOLOL MALEATE | 100 of 2440 | 5630 prescriptions Less than 1% of all prescriptions | | 1340 patients 20% of all patients | < 11 | |
3 DORZOLAMIDE-TIMOLOL (DORZOLAMIDE HCL/TIMOLOL MALEAT) | 220 of 2110 | 2090 prescriptions Less than 1% of all prescriptions | | 630 patients 10% of all patients | < 11 | |
4 LUMIGAN (BIMATOPROST) | 120 of 1750 | 2710 prescriptions Less than 1% of all prescriptions | | 620 patients 9% of all patients | < 11 | |
5 PREDNISOLONE ACETATE | 340 of 2280 | 2640 prescriptions Less than 1% of all prescriptions | | 1740 patients 27% of all patients | < 11 | |
6 COMBIGAN (BRIMONIDINE TARTRATE/TIMOLOL) | 210 of 2040 | 1820 prescriptions Less than 1% of all prescriptions | 1820 | 430 patients 7% of all patients | 430 patients 7% of all patients | |
7 PROLENSA (BROMFENAC SODIUM) | 60 of 670 | 1110 prescriptions Less than 1% of all prescriptions | | 730 patients 11% of all patients | < 11 | |
8 GATIFLOXACIN | 40 of 170 | 1900 prescriptions Less than 1% of all prescriptions | | 1280 patients 20% of all patients | < 11 | |
9 LOTEMAX (LOTEPREDNOL ETABONATE) | 60 of 660 | 1170 prescriptions Less than 1% of all prescriptions | | 690 patients 11% of all patients | < 11 | |
10 RESTASIS (CYCLOSPORINE) | 290 of 1660 | 720 prescriptions Less than 1% of all prescriptions | | 300 patients 5% of all patients | < 11 | |
11 SIMBRINZA (BRINZOLAMIDE/BRIMONIDINE TART) | 70 of 860 | 810 prescriptions Less than 1% of all prescriptions | | 120 patients 2% of all patients | < 11 | |
12 TRAVATAN Z (TRAVOPROST) | 580 of 1800 | 710 prescriptions Less than 1% of all prescriptions | 710 | 160 patients 2% of all patients | 160 patients 2% of all patients | |
13 ILEVRO (NEPAFENAC) | 320 of 860 | 730 prescriptions Less than 1% of all prescriptions | | 490 patients 7% of all patients | < 11 | |
14 ALPHAGAN P (BRIMONIDINE TARTRATE) | 360 of 1340 | 550 prescriptions Less than 1% of all prescriptions | | 130 patients 2% of all patients | < 11 | |
15 OFLOXACIN | 510 of 1060 | 820 prescriptions Less than 1% of all prescriptions | | 640 patients 10% of all patients | < 11 | A |
16 BETOPTIC S (BETAXOLOL HCL) | 20 of 60 | 360 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
17 DORZOLAMIDE HCL | 550 of 1520 | 240 prescriptions Less than 1% of all prescriptions | 240 | 110 patients 2% of all patients | 110 patients 2% of all patients | |
18 VALACYCLOVIR (VALACYCLOVIR HCL) | 160 of 380 | 270 prescriptions Less than 1% of all prescriptions | 270 | < 11 | < 11 | |
19 AZOPT (BRINZOLAMIDE) | 510 of 1380 | 220 prescriptions Less than 1% of all prescriptions | 220 | < 11 | < 11 | |
20 ATROPINE SULFATE | 80 of 290 | 280 prescriptions Less than 1% of all prescriptions | | 280 patients 4% of all patients | < 11 | |
21 RESTASIS MULTIDOSE (CYCLOSPORINE) | 160 of 490 | 230 prescriptions Less than 1% of all prescriptions | 230 | < 11 | < 11 | |
22 PAZEO (OLOPATADINE HCL) | 200 of 640 | 240 prescriptions Less than 1% of all prescriptions | 240 | < 11 | < 11 | |
23 OLOPATADINE HCL | 320 of 900 | 190 prescriptions Less than 1% of all prescriptions | 190 | < 11 | < 11 | |
24 COSOPT PF (DORZOLAMIDE/TIMOLOL/PF) | 150 of 360 | 180 prescriptions Less than 1% of all prescriptions | 180 | < 11 | < 11 | |
25 TOBRAMYCIN-DEXAMETHASONE (TOBRAMYCIN/DEXAMETHASONE) | 310 of 650 | 200 prescriptions Less than 1% of all prescriptions | | 170 patients 3% of all patients | < 11 | |
26 NEOMYCIN-POLYMYXIN-DEXAMETH (NEOMYCIN/POLYMYXIN B/DEXAMETHA) | 550 of 1340 | 320 prescriptions Less than 1% of all prescriptions | 320 | 220 patients 3% of all patients | 220 patients 3% of all patients | |
27 ACETAZOLAMIDE | 330 of 770 | 140 prescriptions Less than 1% of all prescriptions | 140 | < 11 | < 11 | |
28 AZELASTINE HCL | 100 of 190 | 150 prescriptions Less than 1% of all prescriptions | 150 | < 11 | < 11 | |
29 CEPHALEXIN | 40 of 90 | 170 prescriptions Less than 1% of all prescriptions | 170 | 170 patients 3% of all patients | 170 patients 3% of all patients | A |